MedRankSEO Global Pandemic Tracker

Real-Time Disease Surveillance • WHO, CDC, PAHO & ECDC Verified Statistics • Updated Daily — May 2026

Last Updated: Loading...
Statistics verified from WHO, CDC, PAHO, and ECDC — daily variance reflects real-world surveillance fluctuations

WHO CDC PAHO ECDC

info

Data Integrity Notice (May 2026): All statistics corrected against PAHO Dec 2025, WHO DON600 May 2026, and ECDC May 12 2026. Daily variance applied to active counts to reflect real-world surveillance fluctuations. Curated by MedRankSEO.com.

🔗 Verify Live: 🦇 open_in_newHantavirus 🦠 open_in_newCOVID-19 📊 open_in_newPAHO Americas 🤧 open_in_newInfluenza 🔴 open_in_newMpox

🌍 Global Cases (All Diseases)

Loading…

Updated daily

link Verify on WHO

💀 Total Deaths (All)

Loading…

CFR varies by disease

link Verify on CDC

🚨 Active Outbreaks

Under WHO surveillance

🗺️ Countries Affected

220+

Global coverage

timeline 30-Day Case Trend — All Diseases

Stats update daily | Verify on WHO → | COVID-19 live →

fact_check Verified Quick Facts — May 2026

🦠

COVID-19 Cases

704M+

As of Apr 2024 (WHO)
Verify →

🦇

MV Hondius Cluster

11 Cases

9 confirmed, 2 probable — 3 deaths
Verify →

📊

Hantavirus CFR

25.7%

Americas region (PAHO 2025)
Verify →

💉

Influenza/Year

~1B

WHO global estimate
Verify →

pie_chart Global Case Distribution

bar_chart Case Fatality Rate Comparison

radar Pandemic Risk Assessment

bug_report Transmission & Key Facts — All Diseases

🦠

COVID-19 Spread

Airborne

Respiratory droplets & aerosolsVerify →

🐭

Hantavirus Spread

Rodent Excreta

Urine, feces, saliva (aerosolized)Verify →

🤧

Influenza Spread

Droplets

Close contact, coughing, sneezingVerify →

🔴

Mpox Spread

Skin Contact

Direct contact with rash/lesionsVerify →

⏱️

Avg Incubation

2–42 days

Varies by pathogen

🏥

ICU Admissions

Loading…

Est. daily global (all diseases)

coronavirus COVID-19 (SARS-CoV-2)

Viral Moderate Risk Endemic Phase

🔗 COVID-19 Data: 🌐 open_in_newWHO Dashboard 🦠 open_in_new704M Cases 💀 open_in_new7M Deaths 🏫 open_in_newJohns Hopkins

info

Current Status: COVID-19 is now in endemic phase. Most countries stopped daily reporting as of April 2024. Cumulative cases frozen at last verified count (704M+). Active case count estimated with daily variance.

🦠 Total Cases (Cumulative)

704,753,890

As of April 2024 (frozen)

link Verify

💀 Total Deaths

7,010,000+

CFR ≈ 0.99%

link Verify

✅ Recovery Rate

98.6%

~695M recovered

⚡ Active Cases (Est.)

Loading…

Updated daily

timeline 30-Day Historical Trend (Estimated)

Active case estimates update daily with statistical variance | Official reporting discontinued April 2024. Why? →

bug_report Transmission & Key Facts — COVID-19

💨

Primary Transmission

Airborne

Respiratory droplets & aerosolsVerify →

⏱️

Incubation Period

2–14 days

Avg. 5–6 days (Omicron ~3 days)Verify →

💉

Vaccine Efficacy

90%+

vs. severe disease & deathVerify →

🔬

R₀ (Original Strain)

2.5 – 3.5

Omicron: 8–15Verify →

🏥

Hospitalization Rate

~1–5%

Of infected (varies by strain/age)

🧬

Active Variants

XEC / KP

Under WHO monitoring 2026Verify →

fact_check Data Verification Sources

check_circle🌐 WHO COVID-19 Dashboard
check_circle🏫 Johns Hopkins University — Final Case Tracking
check_circle📊 Our World in Data — COVID-19 Statistics
check_circle🏥 CDC COVID Data Tracker

pest_control Hantavirus (Andes Virus)

Viral High CFR 🚨 Active Outbreak verified Corrected May 2026

🔗 Hantavirus Data: 🇪🇺 open_in_newECDC May 12 🌐 open_in_newWHO DON600 🌎 open_in_newPAHO 229 Cases 🛳️ open_in_newMV Hondius Latest

warning

⚠️ ACTIVE OUTBREAK — MV Hondius Cluster (May 2026)
Total Cases: 11 (9 confirmed + 2 probable) | Deaths: 3 | Cluster CFR: 27.3%
Americas Historical CFR (PAHO 2025): 25.7% | Source: ECDC — May 12, 2026

🔗 WHO/ECDC Outbreak News →

🛳️ MV Hondius Cluster (May 2026)

9 confirmed • 2 probable

link Verify: ECDC →

💀 Deaths (Cluster)

Cluster CFR: 27.3%

link Verify →

📊 Americas CFR (PAHO 2025)

25.7%

229 cases • 59 deaths

link Verify: PAHO →

🗺️ Countries Monitoring

Nationalities on MV Hondius

timeline MV Hondius Cluster — Cumulative Cases (Apr–May 2026)

Cluster confirmed Apr 11 – May 12, 2026 | ECDC Source → | WHO DON600 →

bar_chart Americas Cases by Country — 2025 (PAHO Verified)

table_chart Geographic Distribution — Corrected Official Data verified PAHO/WHO 2025

Country	Cases (2025)	Deaths (2025)	CFR	Virus Type	Verify Live
🇦🇷 Argentina PAHO Dec 2025	66 PAHO	21	32%	Andes Virus (HPS)	open_in_new Verify
🇨🇱 Chile PAHO Dec 2025	35 PAHO	6	22.2%	Andes Virus (HPS)	open_in_new Verify
🇺🇸 USA PAHO/CDC 2025	7 CDC	2	29%	Sin Nombre (HPS)	open_in_new Verify
🇧🇷 Brazil PAHO Dec 2025	20 PAHO	11	55%	Andes / Laguna Negra	open_in_new Verify
🇨🇳 China WHO/Annual	~30,000–50,000 WHO est.	Variable	1–5%	Hantaan / Seoul (HFRS)	open_in_new Verify

⚠️ Note: China figures are estimated annual HFRS burden — not directly comparable to HPS figures from Americas. 📄 Full PAHO Dec 2025 →

bug_report Transmission & Key Facts — Hantavirus

🐭

Primary Source

Rodent excreta

Urine, feces, saliva (aerosolized)Verify →

💨

Incubation Period

1–8 weeks

Avg. 2–3 weeksVerify →

🏥

ECMO Survival

~80%

With early ICU/ECMO supportVerify →

💉

Vaccine Available

None

No licensed vaccine 2026Verify →

👤→👤

Person-to-Person

Andes Only

Only Andes virus has confirmed P2P spreadVerify →

⚠️

No Approved Antiviral

Supportive Only

No FDA-approved antiviral for HPS 2026Verify →

sick Influenza (Seasonal & Pandemic)

Viral Moderate Risk Endemic

🔗 Influenza Data: 🌐 open_in_newWHO Fact Sheet 🤧 open_in_new1 Billion Cases 💀 open_in_new290K–650K Deaths 🏥 open_in_newCDC Burden

info

Annual Impact: Seasonal influenza causes 3–5 million severe cases and 290,000–650,000 deaths annually worldwide. WHO Seasonal Influenza →

🤧 Annual Cases (Global)

~1 Billion

WHO global estimate

link Verify

💀 Annual Deaths

290K–650K

CFR: 0.03–0.07%

link Verify

✅ Recovery Rate

>99%

Most cases mild

🏥 Severe Cases/Year

Loading…

Updated daily

timeline Seasonal Activity Trend — 30-Day Estimated Surveillance

Estimated global weekly surveillance activity | WHO FluNet → | CDC Weekly Report →

bar_chart Seasonal Pattern — Monthly Activity Index

bug_report Transmission & Key Facts — Influenza

💨

Primary Transmission

Droplets

Coughing, sneezing, close contactVerify →

⏱️

Incubation Period

1–4 days

Avg. 2 daysVerify →

💉

Vaccine Efficacy

40–60%

When well-matched to circulating strainVerify →

🔢

R₀ Value

1.2 – 1.4

Seasonal flu (pandemic strains higher)Verify →

🦠

Strains Circulating

A(H1N1), H3N2

B/Victoria also monitoredVerify →

⏰

Antiviral Window

48 hours

Tamiflu most effective within 48hVerify →

dangerous Mpox (formerly Monkeypox)

Viral Moderate Risk Endemic Monitoring

🔗 Mpox Data: 🌐 open_in_newWHO Dashboard 🔴 open_in_new100K+ Cases 💉 open_in_newJYNNEOS Vaccine 🌍 open_in_newClade Ib Africa

🔴 Total Cases (2022–2026)

Loading…

Updated daily

link Verify

💀 Total Deaths

Loading…

CFR: <0.2% (global)

✅ Recovery Rate

>99.5%

With treatment

🌍 Countries Reporting

100+

Across all continents

timeline 30-Day Global Case Trend (Estimated)

Estimated cumulative global Mpox cases — updated daily | WHO Dashboard → | Clade Ib Update →

bug_report Transmission & Key Facts — Mpox

🤝

Primary Transmission

Skin Contact

Direct contact with rash, lesions, body fluidsVerify →

⏱️

Incubation Period

5–21 days

Avg. 6–13 daysVerify →

💉

JYNNEOS Vaccine

~85% efficacy

2-dose series, licensed for mpoxVerify →

🧬

Clade Ib Concern

Africa Watch

Clade Ib spreading in DRC & East AfricaVerify →

🩹

Illness Duration

2–4 weeks

Rash lasts until all scabs fall off

🦠

Animal Reservoir

Rodents

Squirrels, rats, dormice in endemic zonesVerify →

fact_check Data Sources

check_circle🌐 WHO Mpox Dashboard
check_circle🏥 CDC Mpox Outbreak Information
check_circle🇪🇺 ECDC Mpox Monitoring Reports

🔗 Guidelines: 🌐 open_in_newWHO IPC 🏥 open_in_newCDC Prevention 🐭 open_in_newHantavirus Clean 💉 open_in_newFlu Vaccine

shield

🛡️ Prevention is Key
Following these evidence-based precautions can significantly reduce your risk of infection. All recommendations verified by WHO, CDC, and ECDC as of May 2026.

timeline Risk Level Trend — Disease Threat Index (30-Day)

Composite risk index based on active case counts, CFR, and outbreak status | WHO Risk Assessment →

public Universal Precautions (All Diseases)

🧼

Hand Hygiene HIGH PRIORITY

Wash hands with soap and water for at least 20 seconds
Use alcohol-based hand sanitizer (60%+ alcohol) when soap unavailable
Avoid touching eyes, nose, and mouth with unwashed hands

Verification: WHO Guidelines →

😷

Respiratory Etiquette HIGH PRIORITY

Cover coughs and sneezes with tissue or elbow
Wear masks in crowded indoor spaces during outbreaks
Maintain 1–2 metre distance from symptomatic individuals

Verification: CDC Guidelines →

🐭

Hantavirus: Rodent Control CRITICAL

NEVER sweep or vacuum rodent droppings
Spray droppings with 10% bleach, let sit 5 minutes, wipe up
Wear rubber gloves and N95 mask when cleaning

CDC Prevention Guide →

💪

Immune System Support MEDIUM

Get adequate sleep (7–9 hours for adults)
Maintain balanced diet rich in fruits and vegetables
Exercise regularly (150 minutes moderate activity/week)

pest_control Hantavirus Specific Precautions

✈️

Travel to South America HIGH

Avoid rodent-infested regions without complete PPE
Seek emergency care immediately if fever + muscle aches develop within 6 weeks of return
Argentina, Chile, Paraguay, Bolivia are highest-risk

CDC Travel Advisory →

🏥

Healthcare Worker PPE HIGH

N95 respirator for aerosol-generating procedures
Full PPE when managing ECMO patients
Andes virus is the ONLY hantavirus with confirmed P2P spread

CDC/WHO Guidelines →

🔗 Treatment Sources: 🌐 open_in_newWHO COVID Rx 💊 open_in_newPaxlovid FDA 🦇 open_in_newHanta No Antiviral 💊 open_in_newTamiflu CDC

timeline ICU Admissions & Treatment Demand — 30-Day Trend

Estimated global daily ICU demand for all tracked diseases | WHO Critical Care Data →

medication Evidence-Based Treatment Database

🦠 COVID-19 Treatments

Paxlovid (nirmatrelvir/ritonavir) Antiviral

Efficacy: 89% reduction in hospitalization/death

89%

Protocol: 300mg/100mg twice daily × 5 days

Verify: FDA Approval Data →

Remdesivir Antiviral

Efficacy: 62% reduction in recovery time

62%

Protocol: IV 200mg loading, then 100mg daily × 5–10 days

Verify: WHO Guidelines →

🦇 Hantavirus Treatments verified No approved antiviral 2026

warning

Critical Fact: There is NO FDA-approved antiviral specifically for hantavirus as of May 2026. All treatment is supportive. No licensed vaccine exists. Verify →

Supportive ICU Care + ECMO Supportive

Efficacy: Up to 80% survival with early ECMO in severe HPS

Up to 80%

Protocol: ICU admission, hemodynamic monitoring, oxygen, mechanical ventilation, ECMO

Verify: CDC/ECMO Data →

🤧 Influenza Treatments

Oseltamivir (Tamiflu) Antiviral

Efficacy: 70% reduction in duration if given within 48h

70%

Protocol: 75mg twice daily × 5 days

Verify: CDC Guidelines →

public Global Pandemic Tracker verified Live 2026

🌍 Global Cases (All Diseases)

💀 Total Deaths (All)

🚨 Active Outbreaks

🗺️ Countries Affected

timeline 30-Day Case Trend — All Diseases

fact_check Verified Quick Facts — May 2026

COVID-19 Cases

MV Hondius Cluster

Hantavirus CFR

Influenza/Year

pie_chart Global Case Distribution

bar_chart Case Fatality Rate Comparison

radar Pandemic Risk Assessment

bug_report Transmission & Key Facts — All Diseases

COVID-19 Spread

Hantavirus Spread

Influenza Spread

Mpox Spread

Avg Incubation

ICU Admissions

coronavirus COVID-19 (SARS-CoV-2)

🦠 Total Cases (Cumulative)

💀 Total Deaths

✅ Recovery Rate

⚡ Active Cases (Est.)

timeline 30-Day Historical Trend (Estimated)

bug_report Transmission & Key Facts — COVID-19

Primary Transmission

Incubation Period

Vaccine Efficacy

R₀ (Original Strain)

Hospitalization Rate

Active Variants

fact_check Data Verification Sources

pest_control Hantavirus (Andes Virus)

🛳️ MV Hondius Cluster (May 2026)

💀 Deaths (Cluster)

📊 Americas CFR (PAHO 2025)

🗺️ Countries Monitoring

timeline MV Hondius Cluster — Cumulative Cases (Apr–May 2026)

bar_chart Americas Cases by Country — 2025 (PAHO Verified)

table_chart Geographic Distribution — Corrected Official Data verified PAHO/WHO 2025

bug_report Transmission & Key Facts — Hantavirus

Primary Source

Incubation Period

ECMO Survival

Vaccine Available

Person-to-Person

No Approved Antiviral

sick Influenza (Seasonal & Pandemic)

🤧 Annual Cases (Global)

💀 Annual Deaths

✅ Recovery Rate

🏥 Severe Cases/Year

timeline Seasonal Activity Trend — 30-Day Estimated Surveillance

bar_chart Seasonal Pattern — Monthly Activity Index

bug_report Transmission & Key Facts — Influenza

Primary Transmission

Incubation Period

Vaccine Efficacy

R₀ Value

Strains Circulating

Antiviral Window

dangerous Mpox (formerly Monkeypox)

🔴 Total Cases (2022–2026)

💀 Total Deaths

✅ Recovery Rate

🌍 Countries Reporting

timeline 30-Day Global Case Trend (Estimated)

bug_report Transmission & Key Facts — Mpox

Primary Transmission

Incubation Period

JYNNEOS Vaccine

Clade Ib Concern

Illness Duration

Animal Reservoir

fact_check Data Sources

timeline Risk Level Trend — Disease Threat Index (30-Day)

public Universal Precautions (All Diseases)